DNER and triple-negative breast carcinoma: Several ongoing clinical trials are designed to test the combination of BET inhibitor ZEN003694 with other therapies in triple-negative breast cancer, including ZEN003694 and MAPK inhibitor Binimetinib (NCT05111561), ZEN003694 and PARP inhibitor Talazoparib (NCT03901469), and ZEN003694 and PD-1 inhibitor Pembrolizumab, in addition to the standard chemotherapy (NCT05422794).